Sec Form 4 Filing - DesJardin Michael A. @ Horizon Therapeutics Public Ltd Co - 2019-12-05

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
DesJardin Michael A.
2. Issuer Name and Ticker or Trading Symbol
Horizon Therapeutics Public Ltd Co [ HZNP]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
EVP, Technical Operations
(Last) (First) (Middle)
C/O HORIZON THERAPEUTICS PLC,, CONNAUGHT HOUSE 1ST FL, 1 BURLINGTON RD
3. Date of Earliest Transaction (MM/DD/YY)
12/05/2019
(Street)
DUBLIN, L24
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 12/05/2019 M 5,860 A 38,686 ( 2 ) D
Ordinary Shares 12/05/2019 F 2,906 ( 3 ) D $ 31.86 35,780 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units ( 1 ) 12/05/2019 M 5,860 ( 4 ) ( 4 ) Ordinary Shares 5,860 $ 0 5,861 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
DesJardin Michael A.
C/O HORIZON THERAPEUTICS PLC,
CONNAUGHT HOUSE 1ST FL, 1 BURLINGTON RD
DUBLIN, L24
EVP, Technical Operations
Signatures
/s/ Miles W. McHugh, Attorney-in-Fact 12/06/2019
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
( 2 )Includes 2,230 ordinary shares of the Issuer which were acquired pursuant to an employee stock purchase program, including 2,119 ordinary shares acquired on May 31, 2019 and 111 ordinary shares acquired on November 29, 2019.
( 3 )Reflects the net settlement of ordinary shares of the Issuer in connection with the vesting of restricted stock units.
( 4 )On December 15, 2016, the reporting person was granted 23,442 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the vesting commencement date of December 5, 2016. The number of shares originally granted under the restricted units was erroneously overstated by one share on the reporting person's prior reports.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.